register

Sales

PRIME Awards revamps sales categories to align with evolving models of HCP engagement

Health Industry Hub | April 5, 2023 |

2023 brings more exciting changes to the PRIME Awards. After careful evaluation and review, the Sales award categories have been reshaped to align with the changing demands on pharma companies, aligning to be more effective across traditional and emerging communications channels with their customers.

The PRIME Committee invited several sales industry bodies within the pharma and life sciences industry and PRIME Awards judges to a roundtable discussion to help redevelop the Sales award categories. An open discussion was had, challenging all aspects of the previous* awards’ entry and judging criteria to make the appropriate changes to make the awards a success in 2023.

The Sales awards are an integral part to the PRIME Awards and they have been revised and refreshed to meet the current and future needs of the commercial function.

The new categories are:

  • Best In-Field Customer Solution – Individual

This award recognises an individual’s performance in delivering an in-field customer solution, and is open to primary or speciality care representatives, MSLs, KAMs, and their managers.

  • Best In-Field Customer Solution – Team

This award recognises a team’s performance in delivering an in-field customer solution, and is open to primary, speciality or MSL teams.

  • Best In-Field Customer Solution – Multidisciplinary Team

This award recognises a multidisciplinary team’s performance in delivering an in-field customer solution and is open to integrated in-field / in-house teams.

Heidi Mawer, Learning & Development Capability Manager at Takeda Pharmaceuticals, said “The judging panel recognised that the industry has evolved significantly. Individuals and teams are engaging with HCPs through varied mediums and in different ways, resulting in a need to revisit the sales categories and criteria in order to do the Awards justice. These revised awards are more representative of the industry and where we are now.”

Malcolm Dawes, Managing Director of dta WORLDWIDE, added “Having been involved with PRIME since its inception, we as judges recognised the need for change. It has been a valuable exercise to refresh these award categories to reflect how the industry is engaging with its customers. It is a testament to all those involved with PRIME that the realignment of the categories was agreed unanimously. I believe we will see a stronger, more vibrant set of entries in 2023 as a result.”

The PRIME Committee and Awards judges are excited to launch the new sales categories in the lead up to the PRIME Awards Ceremony on 9th November which will once again recognise and celebrate innovation and excellence in Australian healthcare communications.  

Health Industry Hub is thrilled to return as the media partner for PRIME Awards 2023.

KEY DATES:

  • Entries Open – Monday 1st May
  • Entries Close – Friday 9th June
  • Judging – June to August
  • Finalists Announced & Tickets on Sale – September
  • PRIME Awards Ceremony – Thursday 9th November, Sydney

*The new sales awards will replace the previous awards below:

  1. Sales Representative of the Year – Primary Care
  2. Representative of the Year – Specialty Care
  3. Team of the Year
  4. Science Liaison of the Year

Medical

NSW Health to settle class action

NSW Health to settle ‘largest’ class action

Health Industry Hub | April 29, 2024 |

A class action alleging NSW Health underpaid clinicians has settled after the department agreed to a payout of nearly a […]

More


News & Trends - Pharmaceuticals

Lilly's first-in-class therapy PBS listed for early breast cancer after 15-year gap

Lilly’s first-in-class therapy PBS listed for early breast cancer after 15-year gap

Health Industry Hub | April 29, 2024 |

Pharma News: Australians diagnosed with early-stage breast cancer, particularly those at high risk of recurrence, will gain access to the […]

More


News & Trends - Pharmaceuticals

AstraZeneza secures four PBAC nods in oncology, diabetes, kidney and rare diseases

AstraZeneza secures four PBAC nods in oncology, diabetes, kidney and rare diseases

Health Industry Hub | April 29, 2024 |

Pharma News: AstraZeneca has scored four positive Pharmaceutical Benefits Advisory Committee (PBAC) recommendations following the March meeting. These recommendations, spanning […]

More


News & Trends - Pharmaceuticals

PBAC recommendation to reshape prescribing in heart failure

PBAC recommendation to reshape prescribing in heart failure

Health Industry Hub | April 29, 2024 |

Pharma News: Aligned with the government’s Scope of Practice Review, the Pharmaceutical Benefits Advisory Committee (PBAC) has made a practice-changing […]

More


This content is copyright protected. Please subscribe to gain access.